Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 29, 24 | 0.67 Increased by +1.52% | 0.60 Increased by +11.67% |
| Feb 22, 24 | 0.45 Decreased by -43.04% | 0.48 Decreased by -6.25% |
| Oct 31, 23 | 0.75 Decreased by -47.92% | 0.65 Increased by +15.38% |
| Aug 1, 23 | 0.56 Increased by +43.59% | 0.63 Decreased by -11.11% |
| May 2, 23 | 0.66 Increased by +29.41% | 0.47 Increased by +40.43% |
| Feb 21, 23 | 0.79 Increased by +107.89% | 0.58 Increased by +36.21% |
| Nov 1, 22 | 1.44 Increased by +947.06% | 0.13 Increased by +1.01 K% |
| Aug 2, 22 | 0.39 Increased by +62.50% | 0.44 Decreased by -11.36% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 160.27 M Increased by +36.74% | 38.46 M Decreased by -56.27% | Increased by +24.00% Decreased by -68.02% |
| Jun 30, 23 | 134.22 M Increased by +25.40% | 34.30 M Increased by +45.77% | Increased by +25.56% Increased by +16.24% |
| Mar 31, 23 | 119.13 M Increased by +39.63% | 29.48 M Increased by +37.24% | Increased by +24.75% Decreased by -1.72% |
| Dec 31, 22 | 128.31 M Increased by +40.67% | 48.51 M Increased by +113.56% | Increased by +37.81% Increased by +51.82% |
| Sep 30, 22 | 117.21 M Increased by +45.18% | 87.94 M Increased by +1.01 K% | Increased by +75.03% Increased by +729.68% |
| Jun 30, 22 | 107.03 M Increased by +44.98% | 23.53 M Increased by +66.69% | Increased by +21.99% Increased by +14.97% |
| Mar 31, 22 | 85.31 M Increased by +42.97% | 21.48 M Increased by +190.89% | Increased by +25.18% Increased by +103.47% |
| Dec 31, 21 | 91.21 M Increased by +62.05% | 22.71 M Increased by +11.13 K% | Increased by +24.90% Increased by +6.90 K% |